Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) was the target of a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 39,500 shares, an increase of 9.7% from the June 30th total of 36,000 shares. Currently, 1.7% of the company’s stock are short sold. Based on an average daily volume of 9,100 shares, the short-interest ratio is presently 4.3 days.
A hedge fund recently raised its stake in Entasis Therapeutics stock. Janney Montgomery Scott LLC increased its stake in Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) by 5.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,917 shares of the company’s stock after acquiring an additional 2,125 shares during the period. Janney Montgomery Scott LLC owned approximately 0.34% of Entasis Therapeutics worth $290,000 as of its most recent SEC filing. 65.04% of the stock is currently owned by institutional investors.
ETTX has been the topic of several recent analyst reports. ValuEngine upgraded Entasis Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Zacks Investment Research downgraded Entasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 20th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Entasis Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $16.50.
Entasis Therapeutics (NASDAQ:ETTX) last released its quarterly earnings results on Monday, August 12th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.44). On average, equities research analysts anticipate that Entasis Therapeutics will post -3.39 earnings per share for the current fiscal year.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
See Also: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.